About Us

Our vision

Armed with a novel approach for resolving inflammation and expertise ranging from drug discovery through FDA approval, we merge future-focused intention with data-driven innovation.

We have earned our reputation by developing Vyleesi® (bremelanotide injection), a novel treatment for women with generalized hypoactive sexual desire disorder (HSDD). We are determined to leverage our unique insight into the industry and the melanocortin system to develop groundbreaking therapeutics for inflammatory and autoimmune diseases, with a focus on ocular conditions.

Leadership

Our management exemplifies the powerful combination of science and business. We support a fast-paced, efficient, nimble, and collaborative working environment that focuses on developing innovative treatments that work with the melanocortin system.

Carl Spana, PhD

Chief Executive Officer, President, and Director

Stephen T. Wills, CPA, MST

Chief Financial Officer, Chief Operating Officer, and Treasurer and Secretary

Stephen Slusher

Chief Legal Officer

Michael Raizman, MD

Chief Medical Officer

John Dodd, PhD

Senior Vice President, Preclinical Development

James Hattersley

Senior Vice President, Business Development

Robert Jordan

Senior Vice President, Program Operations

Paul Kayne, PhD

Vice President, Biological Sciences

Samrat Sisodia, PhD

Vice President Regulatory Affairs and Quality Assurance

J. Don Wang, PhD

VP, Product Development

Board of Directors

Carl Spana, PhD

Chief Executive Officer, President and Director

John K.A. Prendergast, PhD

Director, Chairman of the Board of Directors

Robert K. deVeer, Jr

Director

J. Stanley Hull

Director

Alan W. Dunton, MD

Director

Arlene M. Morris

Director

Anthony M. Manning, PhD

Director

SCIENTIFIC ADVISORY BOARD

Palatin works with leading experts who help shape our research and advise on our clinical development programs.

Scroll to Top